1. Home
  2. MG vs TECX Comparison

MG vs TECX Comparison

Compare MG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mistras Group Inc

MG

Mistras Group Inc

HOLD

Current Price

$18.05

Market Cap

531.0M

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$33.74

Market Cap

618.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MG
TECX
Founded
1978
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
531.0M
618.9M
IPO Year
2008
2018

Fundamental Metrics

Financial Performance
Metric
MG
TECX
Price
$18.05
$33.74
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$75.20
AVG Volume (30 Days)
172.2K
159.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
40.70
EPS
0.30
N/A
Revenue
$700,970,000.00
N/A
Revenue This Year
$5.47
N/A
Revenue Next Year
$3.59
N/A
P/E Ratio
$60.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.96
$14.39
52 Week High
$19.64
$39.53

Technical Indicators

Market Signals
Indicator
MG
TECX
Relative Strength Index (RSI) 62.16 55.80
Support Level $13.37 $27.30
Resistance Level $19.25 $35.99
Average True Range (ATR) 0.83 2.07
MACD 0.38 0.58
Stochastic Oscillator 69.83 65.06

Price Performance

Historical Comparison
MG
TECX

About MG Mistras Group Inc

MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: